Luca Malorni
Overview
Explore the profile of Luca Malorni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
1292
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Scandino R, Nardone A, Casiraghi N, Galardi F, Genovese M, Romagnoli D, et al.
NPJ Breast Cancer
. 2025 Mar;
11(1):25.
PMID: 40057527
Cell-free DNA (cfDNA) extracted from peripheral blood has emerged as a crucial biomarker source in oncology research. To enhance the detection of somatic copy number alterations (SCNAs) and circulating tumor...
2.
Migliaccio I, Guarducci C, Malorni L
Adv Exp Med Biol
. 2025 Jan;
1464():475-493.
PMID: 39821039
The cyclin-dependent kinases 4 and 6 inhibitors are the mainstay of treatment for patients with hormone receptor-positive and HER2-negative breast cancer. The ability of these drugs to improve the outcome...
3.
Livraghi L, Martella F, Ghilli M, Angiolini C, Magnanini S, Moretti E, et al.
Eur J Cancer
. 2024 Nov;
213:115108.
PMID: 39522332
Background: Data published in 2015 showed that patients with early breast cancer (EBC) and a low-risk (LR) Recurrence Score® (RS) result by the 21-gene Oncotype DX® assay ("the test") did...
4.
Gori S, De Rose F, Ferro A, Fabi A, Angiolini C, Azzarello G, et al.
Cancer Treat Rev
. 2024 Oct;
131:102832.
PMID: 39437511
Breast cancer stands as the most frequently diagnosed cancer and the primary cause of cancer-related mortality among women worldwide, including Italy. With the increasing number of survivors, many are enrolled...
5.
Migliaccio I, Romagnoli D, Galardi F, De Luca F, Biagioni C, Curigliano G, et al.
JCO Precis Oncol
. 2024 Mar;
8:e2300285.
PMID: 38427931
Purpose: To identify prognostic circulating biomarkers to cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i), we performed a mutational analysis on circulating tumor DNA (ctDNA) samples from patients included in the...
6.
Bacci M, Lorito N, Smiriglia A, Subbiani A, Bonechi F, Comito G, et al.
Sci Transl Med
. 2024 Feb;
16(736):eadf9874.
PMID: 38416843
Targeting aromatase deprives ER breast cancers of estrogens and is an effective therapeutic approach for these tumors. However, drug resistance is an unmet clinical need. Lipidomic analysis of long-term estrogen-deprived...
7.
Guarducci C, Nardone A, Russo D, Nagy Z, Heraud C, Grinshpun A, et al.
Clin Cancer Res
. 2024 Feb;
30(9):1889-1905.
PMID: 38381406
Purpose: Resistance to endocrine therapy (ET) and CDK4/6 inhibitors (CDK4/6i) is a clinical challenge in estrogen receptor (ER)-positive (ER+) breast cancer. Cyclin-dependent kinase 7 (CDK7) is a candidate target in...
8.
Corti C, De Angelis C, Bianchini G, Malorni L, Giuliano M, Hamilton E, et al.
Cancer Treat Rev
. 2023 May;
117:102569.
PMID: 37146385
Endocrine therapy (ET) is the cornerstone of management in hormone receptor (HR)+ breast cancer (BC). Indeed, targeting the estrogen receptor (ER) signaling at different levels is a successful strategy, since...
9.
Malorni L, Bianchini G, Caputo R, Zambelli A, Puglisi F, Bianchi G, et al.
Eur J Cancer
. 2023 Apr;
186:1-11.
PMID: 37003098
Background: Thymidine kinase 1 (TK1) is an enzyme downstream of the CDK4/6 pathway, with a critical role in DNA synthesis; serum TK1 activity (sTKa) is a novel liquid biopsy biomarker...
10.
Romagnoli D, Nardone A, Galardi F, Paoli M, De Luca F, Biagioni C, et al.
Brief Bioinform
. 2023 Jan;
24(2).
PMID: 36653909
DNA-methylation alterations are common in cancer and display unique characteristics that make them ideal markers for tumor quantification and classification. Here we present MIMESIS, a computational framework exploiting minimal DNA-methylation...